title: CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.
abstract: Minimal residual disease (MRD) has emerged as a major prognostic factor for monitoring patients with B-lineage acute lymphoblastic leukemia (B-ALL). The quantification of MRD by flow cytometry (FC) is based on the identification of a leukemia-associated phenotype (LAP). Because phenotypic switch is common during treatment, multiple LAPs must be available and used for MRD detection over time. We evaluated the potential usefulness of CD304 as a new marker for monitoring MRD. CD304 was expressed in 48% of B-ALL (24/50) with discriminative fluorescence intensity compared with CD304-negative normal B-cell precursors (n = 15). The sensitivity of CD304-based MRD detection reached 10(-4), as with some of established LAPs. The stability of CD304 expression evaluated during therapy and at relapse confirms the usefulness of this marker for MRD quantification. Finally, CD304 was repeatedly expressed in patients with TEL-AML1 gene rearrangement, which warrants further investigation on its potential relevance as a prognosis marker or therapeutic target.
authors: Etablissement Français du sang Bourgogne franche Comté, Laboratoire d'hématologie-immunologie-biologie moléculaire, Besançon, France.
authors: Françoise
authors: F
authors: Solly
authors: Fanny
authors: F
authors: Angelot
authors: Richard
authors: R
authors: Garand
authors: Christophe
authors: C
authors: Ferrand
authors: Estelle
authors: E
authors: Seillès
authors: Françoise
authors: F
authors: Schillinger
authors: Agnès
authors: A
authors: Decobecq
authors: Maryse
authors: M
authors: Billot
authors: Fabrice
authors: F
authors: Larosa
authors: Emmanuel
authors: E
authors: Plouvier
authors: Eric
authors: E
authors: Deconinck
authors: Faezeh
authors: F
authors: Legrand
authors: Philippe
authors: P
authors: Saas
authors: Pierre-Simon
authors: PS
authors: Rohrlich
authors: Francine
authors: F
authors: Garnache-Ottou
mesh_terms: D000293:Adolescent; D000328:Adult; D001402:B-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism*; D019070:Cell Lineage; D050676:Core Binding Factor Alpha 2 Subunit / Q000235:genetics / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D015321:Gene Rearrangement; D006801:Humans; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000175:diagnosis* / Q000378:metabolism; D039942:Neuropilin-1 / Q000276:immunology / Q000378:metabolism*; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000378:metabolism; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D055815:Young Adult; D000097764:ETS Translocation Variant 6 Protein
chemical_list: D015415:Biomarkers; D050676:Core Binding Factor Alpha 2 Subunit; D039942:Neuropilin-1; D015514:Oncogene Proteins, Fusion; C102421:TEL-AML1 fusion protein; D000097764:ETS Translocation Variant 6 Protein